Stoke Therapeutics, Inc. (STOK)
| Market Cap | 1.74B +33.2% |
| Revenue (ttm) | 28.21M -86.3% |
| Net Income | -243.20M |
| EPS | -3.75 |
| Shares Out | 65.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,162,631 |
| Open | 26.49 |
| Previous Close | 26.07 |
| Day's Range | 25.96 - 26.72 |
| 52-Week Range | 21.37 - 40.22 |
| Beta | 1.38 |
| Analysts | Strong Buy |
| Price Target | 46.38 (+74.76%) |
| Earnings Date | Oct 29, 2026 |
About STOK
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome i... [Read more]
Financial Performance
In 2025, Stoke Therapeutics's revenue was $184.42 million, an increase of 404.50% compared to the previous year's $36.56 million. Losses were -$6.89 million, -92.26% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for STOK stock is "Strong Buy." The 12-month stock price target is $46.38, which is an increase of 74.76% from the latest price.
News
Stoke Therapeutics to Present at Upcoming Investor Conferences in November
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics Earnings Call Transcript: Q3 2026
EMPEROR enrollment and retention remain strong, with a Q3 2027 readout and H2 2027 NDA completion planned. Cash of $358.8 million, together with expected Biogen-related receipts, is projected to fund operations into early 2028.
Stoke Therapeutics Slides: Q3 2026
Stoke Therapeutics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Stoke Therapeutics Earnings release: Q3 2026
Stoke Therapeutics released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Stoke Therapeutics Quarterly report: Q3 2026
Stoke Therapeutics has published its Q3 2026 quarterly earnings report on October 29, 2026.
Stoke Therapeutics reports Q EPS ($1.08), consensus (91c)
Reports Q3 revenue $11.3M, consensus $8.2M. “The Phase 3 EMPEROR study of zorevunersen continues to progress well. Approximately 110 of 162 enrolled patients have completed their Week 28 visit when…
Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics announces presentations of data for STK-002
Stoke Therapeutics (STOK) announced two presentations of data for STK-002 at the American Academy of Ophthalmology, AAO, 2026 Annual Meeting, taking place October 9-12 in New Orleans. STK-002 represen...
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today ...
Stoke Therapeutics announces two presentations of data for STK-002 at AAO
Stoke Therapeutics (STOK) announced two presentations of data for STK-002 at the American Academy of Ophthalmology, AAO, 2026 Annual Meeting, taking place October 9-12 in New Orleans. TK-002 is an…
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today ...
Stoke completes meeting with FDA to align aspects with NDA for zorevunersen
Stoke Therapeutics (STOK) announced the completion of a successful meeting with the U.S. Food and Drug Administration, FDA, intended to align on key aspects of the Company’s planned submission of…
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics names Bo Cumbo to board of directors
Stoke Therapeutics (STOK) “announced the appointment of Bo Cumbo to its Board of Directors. Concurrent with Mr. Cumbo’s appointment, Edward Kaye, M.D., has retired from his role as a Director…
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Key milestones include a phase III readout for Dravet syndrome within 12 months and progress in ADOA trials. Zorevunersen shows sustained 75% seizure reduction and functional gains, with OLE data supporting long-term efficacy. The EMPEROR study is well-powered, and commercial strategy leverages robust clinical evidence.
Stoke Therapeutics, Biogen present long-term data on Zorevunersen
“Stoke Therapeutics (STOK) and Biogen Inc. (BIIB) announced presentations of data at the 16th European Epilepsy Congress taking place September 5-9 in Athens, Greece. These data support the potential ...
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
Stoke Therapeutics (STOK) and Biogen (BIIB) announced presentations of data at the 16th European Epilepsy Congress September 5-9 in Athens. These data support the potential of zorevunersen as a first-...
Stoke Therapeutics reinstated with an Overweight at JPMorgan
JPMorgan analyst Jessica Fye reinstated coverage of Stoke Therapeutics (STOK) with an Overweight rating and $40 price target The firm sees a high probability of success for zorevunersen’s Phase III…
Stoke Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference
EMPEROR phase III trial for zorevunersen in Dravet syndrome shows strong retention, zero dropouts, and promising long-term efficacy in both seizure reduction and cognitive gains. Rolling NDA submission is planned for 2027, with long-term data expected to drive value and payer support.
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...